Drug Profile
Research programme: antisense oligonucleotides - Atugen/Novo Nordisk
Alternative Names: Antisense oligonucleotides research programme - Silence Therapeutics/Novo NordiskLatest Information Update: 14 Jul 2010
Price :
$50
*
At a glance
- Originator Atugen; Novo Nordisk
- Class Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 12 Jul 2005 Atugen has been acquired by SR Pharma
- 22 Jan 2002 Preclinical trials in Diabetes mellitus in Denmark (unspecified route)